sorafenib has been researched along with cp 91149 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cp 91149) | Trials (cp 91149) | Recent Studies (post-2010) (cp 91149) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 35 | 0 | 17 |
| Protein | Taxonomy | sorafenib (IC50) | cp 91149 (IC50) |
|---|---|---|---|
| Glycogen phosphorylase, liver form | Homo sapiens (human) | 0.1007 | |
| Glycogen phosphorylase, liver form | Mus musculus (house mouse) | 0.13 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo-Ali, EM; Barot, S; Dukhande, VV; Palaguachi, C; Zhou, DL | 1 |
1 other study(ies) available for sorafenib and cp 91149
| Article | Year |
|---|---|
Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
Topics: Amides; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Glycogen; Glycogen Phosphorylase; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib | 2019 |